🇺🇸 FDA
Patent

US 10208059

Heterocyclic modulators of HIF activity for treatment of disease

granted A61KA61K31/4245A61K31/427

Quick answer

US patent 10208059 (Heterocyclic modulators of HIF activity for treatment of disease) held by The Board of Regents of the University of Texas System expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/4245, A61K31/427, A61K31/437, A61K31/4439